Supply Chain Intelligence

CAMP4 THERAPEUTICS CORPORATION Supply Chain

CAMP supply chain intelligence for CAMP4 THERAPEUTICS CORPORATION: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CAMP ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
6Customers
3Debt Items
13Related Chains

CAMP4 THERAPEUTICS CORPORATION Suppliers

TickerNameConfidenceEvidence
ARE-MA-REGION-NO-75-LLC ARE-MA-REGION-NO-75-LLC 92% the Company entered into a Lease Agreement (the "Watertown Lease") with ARE-MA Region No. 75, LLC ("ARE 75"), an affiliate of ARE 59, for approximately 44,000 rentable square feet of laboratory and o…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 90% On December 18, 2025, CAMP4 Therapeutics Corporation (the “Company”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC (“ Leerink Partners ”), relatin…
FULC Fulcrum Therapeutics, Inc. 72% Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC g…

CAMP4 THERAPEUTICS CORPORATION Customers

TickerNameConfidenceEvidence
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3-LIMIT GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-NO-3-LIMIT 92% GSK has agreed to pay the Company a one-time, non-refundable upfront payment of $17.5 million.
FULCRUM FULCRUM 90% The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) and concluded that the contract counterparty is a customer.
BMRN BioMarin Pharmaceutical Inc. 85% ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license revenue pursuant to the Fulcrum Agreemen…
BMRN BioMarin Pharmaceutical Inc. 85% Reciprocal relationship from BMRN graph: Reciprocal relationship from CAMP graph: ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction pric…
COLLABORATION-AGREEMENTS-BIOMARIN-PHARMACEUTICAL COLLABORATION-AGREEMENTS-BIOMARIN-PHARMACEUTICAL 85% ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license revenue pursuant to the Fulcrum Agreemen…
FULC Fulcrum Therapeutics, Inc. 85% Reciprocal relationship from FULC graph: the Company obtained a worldwide exclusive license to certain intellectual property related to CAMP4's Diamond-Blackfan anemia program

CAMP4 THERAPEUTICS CORPORATION Debt Obligations

InstrumentDescriptionConfidenceEvidence
CAMP-DEBT-8462 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.
CAMP-DEBT Debt stack $2.1M 90% Market cache reports total debt of $2.1M.
CAMP-DEBT-8461 Warrants outstanding: 3601000 90% xbrl warrant detail from xbrl 2025-12-31.

CAMP4 THERAPEUTICS CORPORATION Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for CAMP4 THERAPEUTICS CORPORATION.

CAMP4 THERAPEUTICS CORPORATION Ownership

HolderNameConfidenceEvidence
CAMP-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 47 tracked holders.

CAMP4 THERAPEUTICS CORPORATION Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SANOFI SANOFI 100.00 2
FOLD Amicus Therapeutics Inc 100.00 2
TRDA Entrada Therapeutics, Inc. 100.00 2
SPRB Spruce Biosciences, Inc. 100.00 2
SNYNF Sanofi 100.00 2
PHVS Pharvaris N.V. 100.00 2
GSK GSK plc 50.00 2
SRPT Sarepta Therapeutics, Inc. 50.00 2
LLY Eli Lilly and Company 50.00 2
BMRN BioMarin Pharmaceutical Inc. 45.90 1 ['customer']
FULC Fulcrum Therapeutics, Inc. 38.88 1 ['customer', 'supplier']
BMY Bristol-Myers Squibb Company 20.60 2
BMYMP Bristol-Myers Squibb Co 20.60 2
View CAMP supply chain intel →

Explore the full interactive supply chain map for CAMP4 THERAPEUTICS CORPORATION.

Open CAMP supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map